Researchers from the Universitat de Barcelona and Oregon Health & Science University have developed a novel gene silencing technique using polypurine reverse Hoogsteen hairpins (PPRH) to target and inhibit the expression of PCSK9.
Biomea Fusion Inc. has released preclinical findings from a 28-day weight loss study in obese nonhuman primates evaluating BMF-650, a next-generation oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1RA).
Scientists at Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 1 diabetes, atherosclerosis, type 2 diabetes, obesity, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), hypertension, diabetic complications and coronary heart disease among others.
Ascletis Pharma (China) Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), diabetes, obesity, metabolic syndrome and more.
Ibio Inc. has nominated IBIO-610 as a development candidate for its first-in-class Activin E antibody program and initiated a nonhuman primate (NHP) study.
MBX Biosciences Inc. has submitted an IND application to the FDA for MBX-4291, a long-acting glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonist prodrug for the treatment of obesity.
Diabetic kidney disease (DKD) is a chronic complication of type 1 and type 2 diabetes with albuminuria and progressive kidney failure; about 20%-40% of patients with diabetes will develop some type of kidney disease.
Haisco Pharmaceutical Group Co. Ltd. has disclosed compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes and obesity.
In gout, excessive levels of uric acid in the blood lead to deposition of urate crystals in joints, which can cause strong inflammatory pain. Effectively treating gout involves mitigating not only the pain due to inflammatory responses, but also reducing uric acid levels in the blood, such as by inhibiting the uric acid transporter URAT1.
Obesity is a major public health concern, and effective treatments are still elusive. AMP-activated protein kinase (AMPK) is a crucial regulator of energy homeostasis and has been proposed as a target for metabolic diseases, including obesity. However, most available AMPK agonists target multiple tissues to activate AMPK, which can cause adverse effects.
RSS
